Joachim Boucneau

Pigment cell-related manifestations in neurofibromatosis type 1: an overview.

J. Lambert, J. Naeyaert, L. Messiaen, 2005, Pigment cell research.

Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes.

W. Westbroek, M. Mommaas, J. Lambert, 2006, The Journal of investigative dermatology.

Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind?

J. Lambert, J. Naeyaert, L. Messiaen, 2006, Archives of Dermatological Research.

The NF1 gene and its gene product neurofibromin: towards a functional role in human epidermal melanocytes

Joachim Boucneau, 2006 .

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Joachim Boucneau, N. Kraut, F. Hilberg, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Gene expression profiling of cultured human NF1 heterozygous (NF1+/-) melanocytes reveals downregulation of a transcriptional cis-regulatory network mediating activation of the melanocyte-specific dopachrome tautomerase (DCT) gene.

J. Lambert, J. Naeyaert, S. de Schepper, 2005, Pigment cell research.

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Joachim Boucneau, N. Kraut, F. Hilberg, 2022 .

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Joachim Boucneau, N. Kraut, F. Hilberg, 2022 .

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Joachim Boucneau, N. Kraut, F. Hilberg, 2022 .